Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Feb 28;2013(2):CD008765.
doi: 10.1002/14651858.CD008765.pub3.

Surgical cytoreduction for recurrent epithelial ovarian cancer

Thuria Al Rawahi  1 , Alberto D Lopes, Robert E Bristow, Andrew Bryant, Ahmed Elattar, Supratik Chattopadhyay, Khadra Galaal
Affiliations
Meta-Analysis

Surgical cytoreduction for recurrent epithelial ovarian cancer

Thuria Al Rawahi et al. Cochrane Database Syst Rev. .

Abstract

Background: The standard management of primary ovarian cancer is optimal cytoreductive surgery followed by platinum-based chemotherapy. Most women with primary ovarian cancer achieve remission on this combination therapy. For women achieving clinical remission after completion of initial treatment, most (60%) with advanced epithelial ovarian cancer will ultimately develop recurrent disease. However, the standard treatment of women with recurrent ovarian cancer remains poorly defined. Surgery for recurrent ovarian cancer has been suggested to be associated with increased overall survival.

Objectives: To evaluate the effectiveness and safety of optimal secondary cytoreductive surgery for women with recurrent epithelial ovarian cancer. To assess the impact of various residual tumour sizes, over a range between 0 cm and 2 cm, on overall survival.

Search methods: We searched the Cochrane Gynaecological Cancer Group Trials Register, MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) up to December 2012. We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of included studies and contacted experts in the field. For databases other than MEDLINE, the search strategy has been adapted accordingly.

Selection criteria: Retrospective data on residual disease, or data from randomised controlled trials (RCTs) or prospective/retrospective observational studies that included a multivariate analysis of 50 or more adult women with recurrent epithelial ovarian cancer, who underwent secondary cytoreductive surgery with adjuvant chemotherapy. We only included studies that defined optimal cytoreduction as surgery leading to residual tumours with a maximum diameter of any threshold up to 2 cm.

Data collection and analysis: Two review authors (KG, TA) independently abstracted data and assessed risk of bias. Where possible the data were synthesised in a meta-analysis.

Main results: There were no RCTs; however, we found nine non-randomised studies that reported on 1194 women with comparison of residual disease after secondary cytoreduction using a multivariate analysis that met our inclusion criteria. These retrospective and prospective studies assessed survival after secondary cytoreductive surgery in women with recurrent epithelial ovarian cancer.Meta- and single-study analyses show the prognostic importance of complete cytoreduction to microscopic disease, since overall survival was significantly prolonged in these groups of women (most studies showed a large statistically significant greater risk of death in all residual disease groups compared to microscopic disease).Recurrence-free survival was not reported in any of the studies. All of the studies included at least 50 women and used statistical adjustment for important prognostic factors. One study compared sub-optimal (> 1 cm) versus optimal (< 1 cm) cytoreduction and demonstrated benefit to achieving cytoreduction to less than 1 cm, if microscopic disease could not be achieved (hazard ratio (HR) 3.51, 95% CI 1.84 to 6.70). Similarly, one study found that women whose tumour had been cytoreduced to less than 0.5 cm had less risk of death compared to those with residual disease greater than 0.5 cm after surgery (HR not reported; P value < 0.001).There is high risk of bias due to the non-randomised nature of these studies, where, despite statistical adjustment for important prognostic factors, selection is based on retrospective achievability of cytoreduction, not an intention to treat, and so a degree of bias is inevitable.Adverse events, quality of life and cost-effectiveness were not reported in any of the studies.

Authors' conclusions: In women with platinum-sensitive recurrent ovarian cancer, ability to achieve surgery with complete cytoreduction (no visible residual disease) is associated with significant improvement in overall survival. However, in the absence of RCT evidence, it is not clear whether this is solely due to surgical effect or due to tumour biology. Indirect evidence would support surgery to achieve complete cytoreduction in selected women. The risks of major surgery need to be carefully balanced against potential benefits on a case-by-case basis.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

1
1
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
3
3
Forest plot of comparison: Overall survival, microscopic disease vs. any residual disease (RD).
1.1
1.1. Analysis
Comparison 1 Residual disease (RD) > 0 cm versus microscopic disease, Outcome 1 Overall survival.
2.1
2.1. Analysis
Comparison 2 Residual disease (RD) ≤ 1 cm versus microscopic disease, Outcome 1 Overall survival.
3.1
3.1. Analysis
Comparison 3 Residual disease (RD) ≤ 2 cm versus microscopic disease, Outcome 1 Overall survival.
4.1
4.1. Analysis
Comparison 4 Residual disease (RD) >1 cm versus microscopic disease, Outcome 1 Overall survival.
5.1
5.1. Analysis
Comparison 5 Residual disease (RD) > 2 cm versus microscopic disease, Outcome 1 Overall survival.
6.1
6.1. Analysis
Comparison 6 Residual disease (RD) > 1 cm versus RD ≤ 1 cm, Outcome 1 Overall survival.
7.1
7.1. Analysis
Comparison 7 Overall survival, Outcome 1 Overall survival.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD008765.pub2

References

References to studies included in this review

Ayhan 2006 {published data only}
    1. Ayhan A, Gultekin M, Taskiran C, Aksan G, Celik N, Dursun P, et al. The role of secondary cytoreduction in the treatment of ovarian: Hacettepe University experience. American Journal of Obstetrics and Gynaecology 2006;194:49‐56. - PubMed
Chi 2006 {published data only}
    1. Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum‐sensitive epithelial ovarian carcinoma. Cancer 2006;106(9):1933‐9. - PubMed
Eisenkop 2000 {published data only}
    1. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000;88(1):144‐53. - PubMed
Harter 2006 {published data only}
    1. Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl Si, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Annals of Surgical Oncology 2006;13(12):1702‐10. - PubMed
Oksefjell 2009 {published data only}
    1. Oksefjell H, Sandstad B, Tropé C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2009;20(2):286‐93. - PubMed
Salani 2007 {published data only}
    1. Salani R, Santillan A, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Armstrong DK, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer. Cancer 2007;109(4):685‐91. - PubMed
Scarabelli 2001 {published data only}
    1. Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecologic Oncology 2001;83:504‐12. - PubMed
TIAN 2010 {published data only}
    1. Tian WJ, Jiang R, Cheng X, Tang J, Xing Y, Zang RY. Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1 ‐ 1 cm after secondary cytoreduction. Journal of Surgical Oncology 2010;101:244‐50. - PubMed
Zang 2000 {published data only}
    1. Zang RY, Zhang ZY, Li ZT, Chen J, Tang MQ, Liu Q, et al. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. Journal of Surgical Oncology 2000;75(1):24‐30. - PubMed

References to studies excluded from this review

Benedetti 2006 {published data only}
    1. Benedetti Panici P, Vivo A, Bellati F, Manci N, Perniola G, Basile S, et al. Secondary cytoreductive surgery in patients with platinum‐sensitive recurrent ovarian cancer. Annals of Surgical Oncology 2006;14(3):1136‐42. - PubMed
Berek 1983 {published data only}
    1. Berek JS, Hacker NF, Lagasse LD, Nieberg RK, Elasoff RM. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstetrics & Gynecology 1983;61(2):189‐93. - PubMed
Bristow 2003 {published data only}
    1. Bristow RE, Carmen MG, Pannu HK, Cohade C, Zahurak ML, Fishman EK, et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecologic Oncology 2003;90(3):519‐28. - PubMed
Bristow 2009 {published data only}
    1. Bristow RE, Peiretti M, Gerardi M, Zanagnolo V, Ueda S, Diaz‐Montes T, et al. Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome. Gynecologic Oncology 2009;114(2):173‐7. - PubMed
Eisenkop 1995 {published data only}
    1. Eisenkop S M, Friedman R L, Wang H J. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study. Cancer 1995;76(9):1606‐14. - PubMed
Gadducci 2000 {published data only}
    1. Gadducci A, Lacconi P, Cosio S, Fanucchi A, Cristofani R, Riccardo Genazzani A. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecologic Oncology 2000;79(3):344‐9. - PubMed
Goto 2011 {published data only}
    1. Goto T, Takano M, Watanabe A, Miyamoto M, Kato M, Hirata J, et al. Potential survival benefit of secondary cytoreductive surgery for recurrent epithelial ovarian, tubal, and peritoneal cancers. International Journal of Gynecological Cancer 2011;21:263‐8. - PubMed
Gronlund 2005 {published data only}
    1. Gronlund B, Lundvall L, Christensen IJ, Knudsen JB, Hogdall C. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel‐platinum. European Journal of Surgical Oncology 2005;31(1):67‐73. - PubMed
Gungor 2005 {published data only}
    1. Gungor M, Ortak F, Arvas M, Kosebay D, Sonmezer M, Kose K. The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecologic Oncology 2005;97(1):74‐9. - PubMed
Helm 2007 {published data only}
    1. Helm CW, Randall‐Whitis L, Martin RS 3rd, Metzinger DS, Gordinier ME, Parker LP, et al. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecologic Oncology 2007;105(1):90‐6. - PubMed
Karam 2007 {published data only}
    1. Karam AK, Santillan A, Bristow RE, Giuntoli II R, Gardner GJ, Cass I, et al. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome. Gynecologic Oncology 2007;104(2):377‐80. - PubMed
Landoni 1998 {published data only}
    1. Landoni F, Pellegrino A, Cormio G, Milani R, Maggioni A, Mangioni C. Platin‐based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second‐look laparotomy. Acta Obstetricia et Gynecologica Scandinavica 1998;77(2):233‐7. - PubMed
Matsumoto 2006 {published data only}
    1. Matsumoto A, Higuchi T, Yura S, Mandai M, Kariya M, Takakura K, et al. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum‐based chemotherapy. The Journal of Obstetrics and Gynaecology Research 2006;32(6):580‐7. - PubMed
Morris 1989 {published data only}
    1. Morris M, Gershenson DM, Wharton JT, Copeland LJ, Edwards CL, Stringer CA. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecologic Oncology 1989;34(3):334‐8. - PubMed
Munkarah 2001 {published data only}
    1. Munkarah A, Levenback C, Wolf JK, Bodurka‐Bevers D, Tortolero‐Luna G, Morris RT, et al. Secondary cytoreductive surgery for localized intra‐abdominal recurrences in epithelial ovarian cancer. Gynecologic Oncology 2001;81(2):237‐41. - PubMed
Park 2006 {published data only}
    1. Park JY, Seo SS, Kang S, Lee KB, Yi LS, Seong CH, et al. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Gynecologic Oncology 2006;103(3):977‐84. - PubMed
Tay 2002 {published data only}
    1. Tay EH, Grant PT, Gebski V, Hacker NF. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstetrics and Gynecology 2002;99(6):1008‐13. - PubMed
Tebes 2007 {published data only}
    1. Tebes Stephen J, Sayer Robyn A, Palmer James M, Tebes Christine C, Martino Martin A, Hoffman Mitchel S. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecologic Oncology 2007;106(3):482‐7. - PubMed
Vaccarello 1995 {published data only}
    1. Vaccarello L, Rubin SC, Vlamis V, Wong G, Jones WB, Lewis JL, et al. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecologic Oncology 1995;57(1):61‐5. - PubMed
van der Vange 2000 {published data only}
    1. Vange N, Goethem AR, Zoetmulder FAN, Kaag MM, Vaart PJM, Bokkel Huinink WW, et al. Extensive cytoreductive surgery combined with intra‐operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. European Journal of Surgical Oncology (EJSO) 2000;26(7):663‐8. - PubMed
Zang 2000a {published data only}
    1. Zang R‐Y, Zhang Z‐Y, Li Z‐T, Cai S‐M, Tang M‐Q, Chen J, et al. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer. European Journal of Surgical Oncology (EJSO) 2000;26(8):798‐804. - PubMed
Zang 2003 {published data only}
    1. Zang R‐Y, Li Z‐T, Zhang Z‐Y, Cai S‐M. Surgery and salvage chemotherapy for Chinese women with recurrent advanced epithelial ovarian carcinoma: a retrospective case‐control study. International Journal of Gynecological Cancer 2003;13(4):419‐27. - PubMed
Zang 2004 {published data only}
    1. Zang RY, Li ZT, Tang J, Cheng X, Cai SM, Zhang ZY, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?. Cancer 2004;100(6):1152‐61. - PubMed
Zanon 2004 {published data only}
    1. Zanon C, Clara R, Chiappino I, Bortolini M, Cornaglia S, Simone P, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World Journal of Surgery 2004;28(10):1040‐5. - PubMed

Additional references

Boente 1998
    1. Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Seminars in Oncology 1998;25:326‐34. - PubMed
Bookman 1998
    1. Bookman MA, Malmström H, Bolis G, Gordon A, Lissoni A, Krebs JB, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open‐label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. Journal of Clinical Oncology 1998;16(10):3345‐52. - PubMed
Bristow 2002
    1. Bristow RE, Tomacruz RS, Armstrong DK, Timble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta‐analysis. Journal of Clinical Oncology 2002;20:1248‐59. - PubMed
Burke 1994
    1. Burke TW, Morris M. Secondary cytoreductive surgery for ovarian cancer. Obstetrics and Gynecology Clinics of North America 1994;21:167‐78. - PubMed
CTCAE 2006
    1. Common Terminology Criteria for Adverse Events v3.0. www.eortc.be/services/doc/ctc/ctcaev3.pdf (accessed 23 January 2013).
Deeks 2001
    1. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta‐Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001.
Delgado 1984
    1. Delgado G, Oram DH, Petril ES. Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecologic Oncology 1984;18:293‐8. - PubMed
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7:177‐88. - PubMed
Elattar 2011
    1. Elattar A, Bryant A, Winter‐Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD007565.pub2] - DOI - PMC - PubMed
EUROCARE 2003
    1. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, et al and the EUROCARE Working Group. EUROCARE‐3: survival of cancer patients diagnosed 1990‐94 ‐ results and commentary. Annals of Oncology 2003;14 Suppl 5:v61‐v118. - PubMed
Galaal 2010
    1. Galaal K, Naik R, Bristow RE, Patel A, Bryant A, Dickinson HO. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2010, Issue 6. [DOI: 10.1002/14651858.CD007822.pub2] - DOI - PMC - PubMed
GLOBOCAN 2008
    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. globocan.iarc.fr (accessed 23 January 2013).
Goff 2000
    1. Goff BA, Mander L, Muntz HG. Ovarian carcinoma diagnosis. Cancer 2000;89(10):2068‐75. - PubMed
Gonzalez‐Martin 2003
    1. Gonzalez‐Martin AA, CIavo E, Bover I, Rubio J, Arcusa A, Casado A. Randomized phase II study of carboplatin versus paclitaxel‐carboplatin in platinum sensitive recurrent advanced ovarian carcinoma with assessment of quality of life. Proceedings of the American Society of Clinical Oncology 2003;22:abs 1812.
Hacker 1983
    1. Hacker NF, Berek JS, Lagasse CD, Neiberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstetrics and Gynecology 1983;61:413‐20. - PubMed
Hannibal 2008
    1. Hannibal CG. Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five year relative survival. Acta Obstetricia et Gynecologica Scandinavica 2008;87(12):1353‐60. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60. - PMC - PubMed
Higgins 2008
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
Hoskins 1994
    1. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with sub optimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology 1994;70:974‐80. - PubMed
IARC 2002
    1. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in Five Continents, Volume VIII. IARC Scientific Publication 2002; No. 155 2002. - PubMed
Jemal 2008
    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T. Cancer statistics. CA: A Cancer Journal for Clinicians 2008;58:71‐96. - PubMed
Markman 2004
    1. Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, et al. Duration of response to second‐line, platinum‐based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. Journal of Clinical Oncology 2004;22(15):3120‐5. - PubMed
Munkarah 2004
    1. Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecologic Oncology 2004;95(2):273‐80. - PubMed
Ozols 2005
    1. Ozols RF, Rubin SC, Thomas GM, Robboy SJ. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, Barakat R, Markman M, Randall M editor(s). Principles and Practice of Gynecologic Oncology. 4th Edition. Philadelphia, PA: Lippincott‐Raven Publishers, 2005:895‐987.
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34. - PubMed
Parmar 2003
    1. Parmar MK, Ledermann JA, Colombo N, du Bios A, Delaloye JF, Kristensen GB. Paclitaxel plus platinum‐based chemotherapy versus conventional platinum‐based chemotherapy in women with relapsed ovarian cancer. the ICON4/AGO‐OVAR‐2‐2 trial. Lancet 2003;361:2099‐106. - PubMed
Piver 1988
    1. Piver MS, Lele SB, Marchetti DL, Baker TR, Tsukaso Y, Emrich LJ. The impact of aggressive debulking surgery and cisplatin‐based chemotherapy on progression‐free survival in Stage III and IV ovarian carcinoma. Journal of Clinical Oncology 1988;6:983‐9. - PubMed
RevMan 2011 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Scully 1998
    1. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Atlas of Tumor Pathology. Vol. Fascicle 23 3rd series, Washington, DC: Armed Forces Institute of Pathology, 1998:1‐168.
Shepherd 1989
    1. Shepherd JH. Revised FIGO staging for gynaecological cancer. British Journal of Obstetrics and Gynaecology 1989;96(8):889‐92. - PubMed
Smith 2005
    1. Smith LH, Morris CR, Yasmeen S. Ovarian cancer: can we make the clinical diagnosis earlier?. Cancer 2005;104(7):1398‐407. - PubMed
Vergote 2011
    1. Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. European Journal of Cancer 2011;47 Suppl 3:S88‐92. - PubMed
Wright 2006
    1. Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, et al. Bevacizumab combination therapy in recurrent, platinum‐refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 2006;107(1):83‐9. - PubMed

Publication types

MeSH terms

Substances